The Asia Pacific Newborn Screening Market Continues To Grow Owing To the Increasing Birth Rate in the Region

Asia Pacific Newborn Screening Market

Asia Pacific Newborn Screening Market, by Products Type (Hearing Screening Devices, Mass Spectrometer, Pulse Oximetry, and Assay Kits and Reagents), by Test Type (Phenylketonuria (PKU), Critical Congenital Heart Defect (CCHD), Hearing Screening, Sickle Cell Disease, Maple Syrup Urine Disease (MSUD), Thyroid Disorder, Biotinidase Deficiency (BTD), and Others), by End User (Hospitals, Maternity & Specialty Clinics, and Diagnostic Centers) and by Country (China, Japan, South Korea, ASEAN, India, Australia, and Rest of Asia Pacific)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030.

Market Overview:

Newborn screening is a type of health program, which involves testing newborn babies for several genetic, metabolic, and congenital disorders shortly after birth. The screening is usually done by taking a few drops of blood from the baby's heel, which are then analyzed in a laboratory to identify any abnormalities. The purpose of newborn screening is to detect any potential health problems early on before they cause significant harm to the baby's health or development.

The disorders that are screened for vary by country, but typically include conditions such as phenylketonuria (PKU), congenital hypothyroidism, sickle cell disease, and cystic fibrosis, among others. These disorders may not have noticeable symptoms at birth but can cause serious health problems if left untreated. Early detection and treatment can help prevent or reduce the severity of these conditions.

Competitive Landscape:

Major players operating in the Asia Pacific newborn screening market include ZenTech S.A., Trivitron Healthcare Pvt. Ltd., PerkinElmer Inc., Natus Medical Inc., Masimo Corporation, GE Life Sciences, Covidien PLC, Bio-Rad Laboratories, AB SCIEX, Waters Technologies Corporation, Agilent Technologies, and Medtronic plc.

Key Market Drivers:

The primary driver of the Asia Pacific newborn screening market is the increasing incidence of genetic and metabolic disorders in newborns. The rising awareness among parents and healthcare professionals about the importance of early detection and treatment of these disorders is also fueling the market growth. For instance, according to the World Health Organization, in South-East Asia every year over 8.14 million children are born with birth defects. Additionally, technological advancements in screening techniques and a growing emphasis on healthcare infrastructure development in the Asia Pacific region are estimated to enhance the growth of the Asia Pacific newborn screening market.

Covid-19 Impact Analysis:

The COVID-19 pandemic has significantly impacted the Asia Pacific newborn screening market. The pandemic has led to disruptions in the healthcare system, including delays in screening programs and reduced access to healthcare facilities. However, the pandemic has also led to an increased focus on healthcare infrastructure development, including the expansion of screening programs and the development of new screening technologies.

Key Takeaways:

·         The Asia Pacific newborn screening market is expected to witness significant growth in China and India due to the high birth rates in these countries and the growing focus on healthcare infrastructure development. For instance, according to Macrotrends, the present birth rate in India in 2023 is around 16.949 births per 1000 people.

·         Japan and South Korea are also estimated to witness high growth in the Asia Pacific newborn screening market due to the high prevalence of genetic and metabolic disorders along with the high prevalence of biotechnology companies in these countries. For instance, according to the Japan Bioindustry Association, there are around 1200 biotech startups in Japan currently.